Development of PPAR-agonist GW0742 as antidiabetic drug

Development of PPAR-agonist GW0742 as antidiabetic drug gw0742 GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, μM and 2 μM for human PPARδ, gw0742 Shop 5MG GW0742 at

gw0742 GW0742, >=98% , solid · Biochemphysiol Actions GW0742 is a highly selective PPARδ agonist · Features and Benefits This compound is featured on the

gw0742 As a PPAR delta agonist, GW0742 enhances fatty acid metabolism This in turn preserves blood sugar as well as physical endurance It is because of this effect GW0742 is a PPARδβ agonist that has been investigated for drug use by GlaxoSmithKline GW0742 Clinical data ATC code None Legal status